Navigation Links
Ikaria Appoints Daniel Tasse as President and Chief Executive Officer
Date:1/9/2008

- Former CEO David Shaw Named Executive Chairman and Chairman of the Board

-

CLINTON, N.J., Jan. 9 /PRNewswire/ -- Ikaria Holdings, Inc., a fully integrated critical care biopharmaceutical company, announced today that Daniel Tasse has been appointed President and Chief Executive Officer. Mr. Tasse succeeds David Shaw, who has served as Chairman and interim CEO since the creation of Ikaria Holdings in March 2007 and will now serve as Executive Chairman and Chairman of the Board.

Mr. Shaw commented, "Daniel is an outstanding fit for the Ikaria opportunity, and vice versa. He has extensive executive management experience in 'academy companies' in the pharmaceutical and life sciences industry, with highly relevant expertise in R&D management, marketing and sales, and other functions in domestic and international markets. We expect to benefit strategically and operationally from Daniel's many years of involvement in both drugs and devices across many therapeutic areas and healthcare settings, including critical care. His leadership capabilities and his knowledge of in- hospital markets will be particularly valuable as Ikaria continues to build an exceptionally strong capability to serve the needs of critically ill patients."

Daniel Tasse stated, "The formation of Ikaria last year created a company with the potential to redefine the critical care industry. With Ikaria's industry-leading INOmax(R) product and a pipeline of unique therapeutic compounds and numerous business development and R&D opportunities, we have a very exciting and unique opportunity available to us. I feel very fortunate to join this team in a leadership position with the goal of building a legendary company in the years ahead."

Mr. Tasse most recently served as the General Manager of Baxter International's $2 billion Pharmaceuticals & Technologies business, a division created by integrating the company's Anesthesia, Critical Care
'/>"/>

SOURCE Ikaria Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Ikaria to Present at 26th Annual JPMorgan Healthcare Conference
2. Ikaria Founding Scientist Named 2007 MacArthur Fellow
3. New Study Shows Promise for Hydrogen Sulfide in Reducing Heart-Attack Damage, Ikaria Announces
4. SRA Names Timothy J. Atkin Senior Vice President of Global Health Business; Appoints Mike Toner Global Health Unit Chief Financial Officer
5. Mersana Therapeutics Appoints C. Boyd Clarke Chairman of the Board of Directors
6. Chimerix Appoints Neil Frazer, M.B., Ch.B., FRCA, FFPM as Chief Medical Officer
7. Access Pharmaceuticals Appoints Jeffrey B. Davis as CEO
8. Seahorse Bioscience Appoints Former Molecular Devices Executive Dr. Joseph D. Keegan to Board of Directors
9. Kendle Appoints Former MHRA Head of Biologics as Principal Regulatory Affairs Consultant
10. LeMaitre Vascular Appoints Russell D. Hays to Its Board of Directors
11. SGX Pharmaceuticals Appoints Joseph L. Turner to Board of Directors

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)... Peregrine Pharmaceutical...ill release its financial results for the second q... 7:00 a.m. EST and will host a conference call and...on the same day. ,, Peregrine,s senior manageme...uarter ended October 31, 2009 and will review rece...
(Date:12/2/2009)...Newswire-FirstCall/ -- Martek Biosciences Corporat...ds to release the results of its fourth quarter an...imately 4:00 p.m. Eastern Time (ET). Following th...onference call to discuss these results with inves...ll live via webcast by visiting Martek,s web site ...
(Date:12/2/2009)...ewswire/ -- Reportlinker.com announces that a new ...ue: ,, Drug Discovery Technologies - A Global ... http://www.reportlinker.com/p0164246/Drug-Discov...s--Opportunities.html ,, Drug discovery has be...maceutical company,s business strategy. There are ...
(Date:12/2/2009)...ewswire-FirstCall/ - Oncolytics Biotech Inc. ("Onc...) announced today that in connection with its prev...ave exercised in full their over-allotment option ...it is comprised of one common share and 0.4 of a c...ice of US$3.00 per unit. Each whole common share p...
Breaking Biology Technology:Peregrine Pharmaceuticals to Report Second Quarter FY 2010 Financial Results 2Martek to Announce Fourth Quarter and Fiscal Year 2009 Results 2Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 2Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 3Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 4Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 5Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 6Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 7Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 8Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 9Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 2Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 3Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 4
...eb. 11 Caliper Life,Sciences, Inc. (Nasdaq: CALP...utsche Bank 2008 Small and Mid Cap Growth Conferen..., February 13 at 4:40 p.m. EST. Kevin,Hrusovsky, P...update on the,company,s business. The live webcast...reye/confLobby.zhtml?ticker=CALP&item_id=17485 ,73...
...s Potential New Short-Course Treatment Option for ...luding MRSA, CAMBRIDGE, Mass., Feb. 11 Targanta,...d today that it has,submitted a New Drug Applicati...(FDA) for its lead antibiotic candidate, oritavanc...otic candidate with potent,bactericidal (killing) ...
...e real-world clinical data on the PROMUS(TM) Stent...ration (NYSE: BSX ) today announced that the firs...(TM), ENdeavor(R) and CYpher(R)) European,registry...Olimus,-eluting,coronary stents. It will collect r...ic,s PROMUS(TM) Everolimus-Eluting Coronary Stent ...
Other Biology Technology:Targanta Submits Oritavancin New Drug Application 2Targanta Submits Oritavancin New Drug Application 3Targanta Submits Oritavancin New Drug Application 4Boston Scientific Announces Start of Major European Registry Assessing Different Olimus-Eluting Stents 2Boston Scientific Announces Start of Major European Registry Assessing Different Olimus-Eluting Stents 3Boston Scientific Announces Start of Major European Registry Assessing Different Olimus-Eluting Stents 4
(Date:12/3/2009)... snubbing? Your genetics, not your friends, may be...um-like painkillers, called opioids, relieve not o...l stress. Now, a new study reviewed by Faculty of ... genetic differences in the gene for the opioid re...ponses to social rejection. , In the study publ...
(Date:12/3/2009)...estment in energy efficient technologies research,...uncil (EPSRC) Chief Executive Dave Delpy believes ...esearch has already brought us fuel cells, marine,...nt is needed to develop the capabilities of differ...n targets by 2020 and limit the impact of climate ...
(Date:12/2/2009)...and cigarette smoke have an increased risk of deve...r smoked. , Results of this study are published..., a journal of the American Association for Cancer...he December issue. , This year alone, more than...cer; more than 159,000 will die from it and some o...
Breaking Biology News(10 mins):Research is vital to a cleaner, greener, low carbon future 2Secondhand smoke exposure in childhood increases lung cancer risk later in life 2Sugarcane as a Key Element Against Global Warming to be Highlighted at Green Week in Brussels 12749 1Sugarcane as a Key Element Against Global Warming to be Highlighted at Green Week in Brussels 12749 2Sugarcane as a Key Element Against Global Warming to be Highlighted at Green Week in Brussels 12749 3Sugarcane as a Key Element Against Global Warming to be Highlighted at Green Week in Brussels 12749 4Need something 3F Talk to my right ear 21 49772 1Need something 3F Talk to my right ear 21 49772 2Lack of happiness hormone serotonin in the brain causes impaired maternal behavior in mice 8972 1
...ockfish (Sebastes sp.) took place in the Central G...corporated fishery cooperatives instead of the usu...dicate increased retention rates, reduced bycatch ...ther benefits to the Kodiak Island community. , I... in slowing the pace of the fishery, improving pro...
... with blue eyes have a single, common ancestor. A ...down a genetic mutation which took place 6-10,000 ...l blue-eyed humans alive on the planet today. , ...l had brown eyes, said Professor Eiberg from the D... genetic mutation affecting the OCA2 gene in our c...
...ted to the framed journal covers decorating his of...ting, complicated structure of an enzyme. Those br...s lab. And theyre part of Reillys work to understa...echanism and its activity. , In other words, hes...work, said Reilly, a professor of chemical and bio...
Other Biology News:A pilot program for harvesting Kodiak rockfish 2A pilot program for harvesting Kodiak rockfish 3Blue-eyed humans have a single, common ancestor 2Iowa State researcher studies how enzymes break down cellulose 2
PCNA Immunohistochemistry Assay Kit from Invitrogen
Varian Cary 6000i Spectrophotometer from Varian, Inc.
Gln(Trt) Peptide Synthesis Column from Applied Biosystems
E. coli Expression System with Gateway Technology from Invitrogen
Biology Products: